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or reduced ankle blood pressure affects around 20% of
the elderly population; however, only around 6%
report symptoms of intermittent claudication.1 Thus,
while the results of imaging may give information
relevant to the risk of cardiovascular events and the
technical success of an invasive intervention on
patients with peripheral vascular disease, it will not
provide a measure of symptomatic outcome. Two
types of outcome measures have been suggested in
patients with intermittent claudication, namely objec-
tive measures of walking distance and subjective
symptomatic assessments.2
The need for patient-assessed health outcomes of
intermittent claudication has been appreciated for
some time and has led to the increasing use of both
generic and more specific health-related quality of life
questionnaires.3 The most frequently utilised and
relevant generic quality of life questionnaire is the
Short Form-36 (SF-36).4 Such generic instruments have
the advantage of being well validated for the overall
assessment of quality of life but may not provide
information specific to intermittent claudication and
thereby, not be responsive to changes after therapeutic
interventions. In order to improve outcome assess-
ment of intermittent claudication, a number of disease-
specific questionnaires have been developed.5–7 In this
issue of The European Journal of Vascular and
Endovascular Surgery, Mehta and colleagues report a
study in which various disease-specific and generic
questionnaires are compared as outcome measures for
70 patients undergoing treatment of intermittent
claudication.8 The authors correlate the questionnaire
scores with each other and also with treadmilling author. Associate Professor Jonathan Golledge,
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(ICD) and maximal walking distance (MWD). Mehta
et al. also analyse how these assessments change in
response to treatment.
Assessment of the validity and responsiveness of
such questionnaires is not straightforward. Since
there is no current gold standard for outcome
assessment in intermittent claudication it is conten-
tious as to what measures should be compared with
the quality of life (QOL) scores. As in previous
validation studies, the authors have used the ICD
and MWD determined during a treadmill-walking
test as the criterion measures. This is reasonable
given that improving functional capacity is a primary
goal of therapy in patients with intermittent claudi-
cation. However, this also assumes that QOL in PVD
patients is determined only by their walking
tolerance, which is not likely to be the case; more-
over, there will also be natural variance between
QOL and functional capacity. The methods used to
determine ICD and MWD also impact upon their
usefulness as criterion measures. Constant load
walking tests, such as that used by Mehta et al.,
have been shown by some to be more variable than
incremental walking tests.9,10 Furthermore, the mag-
nitude and variability of MWD and ICD changes
with test familiarisation or training and can be
influenced by subtle test protocol variations.11 For
this reason, it is recommended that a stable baseline
for treadmill walking distances be achieved prior to
clinical trials,12 and the same should be done when
these measures are being used as a criterion measure
to validate QOL assessment tools.
While the authors tested validity against MWD,
they assessed the responsiveness of the QOL
measures with the International Society of Cardio
Vascular Surgery criteria, which were designed toEur J Vasc Endovasc Surg 31, 44–45 (2006)
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and include ankle pressure criteria. Using this
approach Mehta and colleagues conclude that the
VASCUQOL is the most responsive disease-specific
questionnaire and, therefore, recommend its use in
clinical practice. Support for this recommendation is
provided in a recent study by de Vries and
colleagues, in which they compared the SF-36, the
EUROQUOL and the VASCUQOL in over 400
patients with intermittent claudication.13 Using
different analysis methods, de Vries et al. reported
the VASCUQOL to be more responsive to changes in
intermittent claudication symptoms than the generic
instruments.13
The VASCUQOL was originally developed as a
disease-specific quality of life measure for lower limb
ischaemia.5 Around half of the patients used in the
development and validation of this instrument had
rest pain, ischaemic ulceration or gangrene and,
therefore, the resultant 25 item questionnaire includes
some questions related to pain at rest, ulceration and
limb loss. Since, these questions are not very relevant
to patients with intermittent claudication, and were
not associated with disease deterioration in Mehta and
colleagues study, it could be argued that a more
specific questionnaire is warranted. Chong and
colleagues developed a quality of life instrument
specific for intermittent claudication in 124 patients
and reported good validity and responsiveness by
comparison to symptoms and generic instruments.7
The resultant questionnaire has the advantage of being
time efficient and relevant to intermittent claudication
as it includes only 16 items related to the effect of leg
pain on activity. A study comparing the VASCUQOL
and intermittent claudication questionnaire is
required.
Mehta and colleagues should be commended for
attempting to bring about standardisation in the use of
patient-focused assessment techniques. To reach this
end, a better understanding of the determinants of
QOL in patients with PVD of varying severity is
required. Studies adopting reliable criterion measures
and assessments of other validated measures of
disease specific QOL, such as the intermittent claudi-
cation questionnaire, would be advisable prior to
making firm conclusions on the most appropriate
disease-specific quality of life instrument to assess
intermittent claudication.Acknowledgements
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